The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Open accessAbstract
Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors.Nevertheless, although somatostatin analogs effectively control hormonal hypersecretion by GH-secreting pituitary adenomas, islet cell tumors, and carcinoid tumors, significant differences are observed among patients with respect to the efficacy of treatment.This may be related to a differential expression of somatostatin receptor subtypes among tumors.In addition, the property of somatostatin receptor subtypes to undergo agonist-induced internalization has important con-sequences for visualizing, as well as for therapy, of receptorpostive tumors using radioisotope-or chemotherapeuticcompound-coupled somatostatin analogs.This review covers the pathophysiological role of somatostatin receptor subtypes in determining the efficacy of treatment of patients with somatostatin receptor-positive tumors using somatostatin analogs, as well as the preclinical and clinical consequences of agonist-induced receptor internalization for somatostatin receptor-targeted radio-and chemotherapy.Herein, the development and potential role of novel somatostatin analogs is discussed.(Endocrine Reviews 24: 28 -47, 2003) I. General Introduction A. SS and sst subtypes B. SS receptor subtype expression in normal and tumorous human tissues C. Agonist-induced internalization of sst subtypes II.Consequences of sst Internalization for sst-Targeted Radiotherapy or Chemotherapy of sst-Positive Tumors A. Preclinical evidence for internalization of radiolabeled SS-analogs B. SS receptor-targeted radiotherapy C. SS receptor-targeted chemotherapy: preclinical evidence III.Tachyphylaxis and Resistance to SS A. Introduction B. Tachyphylaxis of pathological hormone secretion C. Escape from antiproliferative effects D. Mechanisms of tachyphylaxis and resistance E. New developments F. Conclusions IV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Self-citationEndocytosis and the recycling of plasma membrane.
Steinman, R. M., Mellman, I. S., Muller, W. A., & Cohn, Z. A. (1983) · The Journal of cell biology · doi:10.1083/jcb.96.1.1 · Cited by 1,450
Turning off the signal: desensitization of β‐adrenergic receptor function
Hausdorff, W. P., Caron, M. G., & Lefkowitz, R. J. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.11.2165947 · Cited by 1,249
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
THE ROLE OF RECEPTOR KINASES AND ARRESTINS IN G PROTEIN–COUPLED RECEPTOR REGULATION
Krupnick, J. G., & Benovic, J. L. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.289 · Cited by 1,103
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312153092406 · Cited by 1,044
Two G Protein Oncogenes in Human Endocrine Tumors
Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grünewald, K., Feichtinger, H., Duh, Q.-Y., Clark, O. H., Kawasaki, E., Bourne, H. R., et al. (1990) · Science · doi:10.1126/science.2116665 · Cited by 1,037
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Self-citationRocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., & Patel, Y. C. (2000) · Science · doi:10.1126/science.288.5463.154 · Cited by 888
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
LAMBERTS, S. W. J., KRENNING, E. P., & REUBI, J.-C. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-4-450 · Cited by 805
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625
Self-citationMolecular Biology of Somatostatin Receptors*
REISINE, T., & BELL, G. I. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-427 · Cited by 618
Classification and nomenclature of somatostatin receptors
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey, P. P. A., O'Carroll, A.-M., Patel, Y. C., Schonbrunn, A., Taylor, J. E., et al. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88988-9 · Cited by 570
Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers
Rocheville, M., Lange, D. C., Kumar, U., Sasi, R., Patel, R. C., & Patel, Y. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7862 · Cited by 527
Thyrotropin-Secreting Pituitary Tumors*
BECK-PECCOZ, P., BRUCKER-DAVIS, F., PERSANI, L., SMALLRIDGE, R. C., & WEINTRAUB, B. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-6-610 · Cited by 491
Karnofsky memorial lecture. An odyssey in the land of small tumors.
Moertel, C. G. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1502 · Cited by 473
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Somatostatin in the central nervous system: Physiology and pathological modifications
Epelbaum, J. (1986) · Progress in Neurobiology · doi:10.1016/0301-0082(86)90012-2 · Cited by 466
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Yttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Molecular pharmacology of somatostatin receptor subtypes
Patel, Y. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03350317 · Cited by 409
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization.
Yu, S. S., Lefkowitz, R. J., & Hausdorff, W. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54155-7 · Cited by 390
The somatostatin receptor family
Patel, Y. C., Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H., & Srikant, C. B. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02082-t · Cited by 367
Endocytosis and recycling of G protein-coupled receptors
Koenig, J. A., & Edwardson, J. M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01091-2 · Cited by 357
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Patel, Y. C., & Srikant, C. B. (1994) · Endocrinology · doi:10.1210/endo.135.6.7988476 · Cited by 348
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E., Herrmann, R., & Maecke, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78355-0 · Cited by 335
G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins
Ferguson, S. S. G., Barak, L. S., Zhang, J., & Caron, M. G. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-74-10-1095 · Cited by 330
Homo- and Heterodimerization of Somatostatin Receptor Subtypes
Pfeiffer, M., Koch, T., Schröder, H., Klutzny, M., Kirscht, S., Kreienkamp, H., Höllt, V., & Schulz, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006084200 · Cited by 319
Shimon, I., Taylor, J. E., Dong, J. Z., Bitonte, R. A., Kim, S., Morgan, B., Coy, D. H., Culler, M. D., & Melmed, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119225 · Cited by 309
G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins
Ferguson, S., Barak, L. S., Zhang, J., & Caron, M. G. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y96-124 · Cited by 294
Kumar, U., Sasi, R., Suresh, S., Patel, A., Thangaraju, M., Metrakos, P., Patel, S. C., & Patel, Y. C. (1999) · Diabetes · doi:10.2337/diabetes.48.1.77 · Cited by 284
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
Schally, A., & Nagy, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410001 · Cited by 271
Cloning and expression of a novel mouse somatostatin receptor (SSTR2B)
Vanetti, M., Kouba, M., Wang, X., Vogt, G., & Höllt, V. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81122-3 · Cited by 269
Kubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., Imura, H., Seino, S., & Seino, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117090 · Cited by 269
Sharma, K. (1996) · Molecular Endocrinology · doi:10.1210/me.10.12.1688 · Cited by 269
LAMBERTS, S. W. J. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-4-417 · Cited by 265
Self-citationPfeiffer, M., Koch, T., Schröder, H., Laugsch, M., Höllt, V., & Schulz, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110373200 · Cited by 263
Shimon, I., Yan, X., Taylor, J. E., Weiss, M. H., Culler, M. D., & Melmed, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119779 · Cited by 260
Cellular biology of somatostatin receptors
Csaba, Z., & Dournaud, P. (2001) · Neuropeptides · doi:10.1054/npep.2001.0848 · Cited by 250
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
Krenning, E. P., de Jong, M., Kooij, P. P. M., Breeman, W. A. P., Bakker, W. H., de Herder, W. W., van Eijck, C. H. J., Kwekkeboom, D. J., Jamar, F., Pauwels, S., et al. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s23 · Cited by 234
Dual pathways of internalization of the cholecystokinin receptor.
Roettger, B. F., Rentsch, R. U., Pinon, D., Holicky, E., Hadac, E., Larkin, J. M., & Miller, L. J. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1029 · Cited by 232
Wymenga, A. N. M., Eriksson, B., Salmela, P. I., Jacobsen, M. B., Van Cutsem, E. J. D. G., Fiasse, R. H., Välimäki, M. J., Renstrup, J., de Vries, E. G. E., & Öberg, K. E. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1111 · Cited by 226
Somatostatin receptor subtype gene expression in pituitary adenomas
Miller, G. M. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.4.1386 · Cited by 220
Chanson, P., Weintraub, B. D., & Harris, A. G. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-3-199308010-00010 · Cited by 212
Expression of somatostatin receptor subtypes in human brain tumors
Dutour, A., Kumar, U., Panetta, R., Ouafik, L., Fina, F., Sasi, R., & Patel, Y. C. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<620::aid-ijc2>3.0.co;2-s · Cited by 211
[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy
de Jong, M., Breeman, W. A. P., Bernard, B. F., Bakker, W. H., Schaar, M., van Gameren, A., Bugaj, J. E., Erion, J. L., Schmidt, M. A., Srinivasan, A., et al. (2001) · International Journal of Cancer · Cited by 210
Molecular pharmacology of somatostatin receptors
Hoyer, D., L�bbert, H., & Bruns, C. (1994) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00173012 · Cited by 210
de Jong, M., Breeman, W. A., Bakker, W., Kooij, P. P. M., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., et al. (1998) · PubMed · Cited by 209
Self-citationReceptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
Paganelli, G., Zoboli, S., Cremonesi, M., Bodei, L., Ferrari, M., Grana, C., Bartolomei, M., Orsi, F., De Cicco, C., Mäcke, H. R., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100490 · Cited by 206
Ruszniewski, P., Ducreux, M., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., Raymond, J. M., Dupas, J. L., Gouerou, H., Jian, R., et al. (1996) · Gut · doi:10.1136/gut.39.2.279 · Cited by 206
Somatostatin: Physiological and Clinical Significance
Guillemin, R., & Gerich, J. E. (1976) · Annual Review of Medicine · doi:10.1146/annurev.me.27.020176.002115 · Cited by 201
Greenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.3.724 · Cited by 190
Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
Panetta, R., & Patel, Y. C. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00956-2 · Cited by 185
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
Greenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.398 · Cited by 180
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide1
Caron, P. J., Morange, I., Cogne, M., & Jaquet, P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3714 · Cited by 179
Molecular biology of somatostatin receptors
Reisine, T. (1995) · Endocrine Reviews · doi:10.1210/er.16.4.427 · Cited by 179
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
Fløgstad, A. K., Halse, J., Bakke, S. J., Lancranjan, I., Marbach, P., Bruns, C., & Jervell, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3572 · Cited by 176
Hukovic, N. (1996) · Endocrinology · doi:10.1210/en.137.9.4046 · Cited by 168
Saveanu, A., Gunz, G., Dufour, H., Caron, P., Fina, F., Ouafik, L., Culler, M. D., Moreau, J. P., Enjalbert, A., & Jaquet, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7099 · Cited by 168
Treatment of Metastatic Islet Cell Carcinoma with a Somatostatin Analogue (SMS 201-995)
KVOLS, L. K., BUCK, M., MOERTEL, C. G., SCHUTT, A. J., RUBIN, J., O'CONNELL, M. J., & HAHN, R. G. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-162 · Cited by 168
Patel, Y. C., Greenwood, M., Kent, G., Panetta, R., & Srikant, C. B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1412 · Cited by 164
FENESTRATED TRACHEOSTOMY TUBES
LANGE, M. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90918-5 · Cited by 153
Schaer, J., Waser, B., Mengod, G., & Reubi, J. C. (1997) · International Journal of Cancer · Cited by 151
Nagy, A., Schally, A. V., Halmos, G., Armatis, P. E., Cai, R., CSERNUS, V. J., Kovács, M., Koppán, M., Szepesházi, K., & Kahán, Z. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1794 · Cited by 146
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly
Davies, P. H. O., Stewart, S. E., Lancranjan, I., Sheppard, M. C., & Stewart, P. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00389.x · Cited by 137
Pharmacological properties of two cloned somatostatin receptors.
Rens‐Domiano, S., Law, S. F., Yamada, Y., Seino, S., Bell, G. I., & Reisine, T. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08856-x · Cited by 135
Dournaud, P., Boudin, H., Schönbrunn, A., Tannenbaum, G. S., & Beaudet, A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-03-01056.1998 · Cited by 125
Octreotide Long-Acting Release (LAR)
Gillis, J. C., Noble, S., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753040-00009 · Cited by 125
Sharma, K., & Srikant, C. B. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980413)76:2<259::aid-ijc14>3.0.co;2-7 · Cited by 124
Endocytosis and recycling of G protein-coupled receptors
Koenig, J., & Edwardson, J. M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90643-x · Cited by 124
Sharma, K. H., Patel, Y., & Srikant, C. B. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.1.0220 · Cited by 123
Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.
Gallardo, D., Drazan, K. E., & McBride, W. H. (1996) · PubMed · Cited by 114
Wagener, C., Bargou, R. C., Daniel, P. T., Bommert, K., Mapara, M. Y., Royer, H. D., & D�rken, B. (1996) · International Journal of Cancer · Cited by 113
Nilsson, O., Kölby, L., Wängberg, B., Wigander, A., Billig, H., William‐Olsson, L., Fjälling, M., Forssell-Aronsson, E. B., & Ahlman, H. K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.101 · Cited by 111
Glucocorticoids Down-Regulate Somatostatin Receptors on Pituitary Cells in Culture*
Schönbrunn, A. (1982) · Endocrinology · doi:10.1210/endo-110-4-1147 · Cited by 109
Somatostatin receptors in human prostate and prostate cancer.
Reubi, J. C., Waser, B., Schaer, J., et al. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673428 · Cited by 106
Kwekkeboom, D. J., Kooij, P. P. M., Bakker, W., Mäcke, H. R., & Krenning, E. P. (1999) · PubMed · Cited by 106
Reubi, J. C., Laissue, J. A., Waser, B., Horisberger, U., & Schaer, J. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17262.x · Cited by 106
Hofland, L. J., van Koetsveld, P. M., Waaijers, M., Zuyderwijk, J., Breeman, W. A. P., & Lamberts, S. W. J. (1995) · Endocrinology · doi:10.1210/endo.136.9.7649075 · Cited by 100
Self-citationOctreotide exerts different effects in vivo and in vitro in Cushing's disease
Stalla, G. K., Brockmeier, S. J., Renner, U., Newton, C., Buchfelder, M., Stalla, J., & Müller, O. A. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300125 · Cited by 96
Roth, A. J. K., Kreienkamp, H., Meyerhof, W., & Richter, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23769 · Cited by 95
Epelbaum, J., Bertherat, J. Y., Prevost, G. P., Kordon, C., Meyerhof, W., Wulfsen, I., Richter, D., & Plouin, P. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.6.1837 · Cited by 92
Duncan, J. R., Stephenson, M. T., Wu, H. P., et al. (1997) · PubMed · Cited by 88
New advances in peptide receptor radionuclide therapy.
de Jong, M., & Krenning, E. P. (2002) · PubMed · Cited by 88
Andersson, P., Forssell-Aronsson, E. B., Johanson, V., et al. (1996) · PubMed · Cited by 88
Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.
Fjälling, M., Andersson, P., Forssell-Aronsson, E. B., Grétarsdóttir, J., Johansson, V., Tisell, L. E., Wängberg, B., Nilsson, O., Berg, G., Michanek, A., et al. (1996) · PubMed · Cited by 87
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.
Breeman, W. A., Kwekkeboom, D. J., Kooij, P. P. M., Bakker, W. H., Hofland, L. J., Visser, T. J., Ensing, G. J., Lamberts, S. W. J., & Krenning, E. P. (1995) · PubMed · Cited by 86
Self-citationDOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy1
Smith-Jones, P. M., Bischof, C., Leimer, M., et al. (1999) · Endocrinology · doi:10.1210/endo.140.11.7126 · Cited by 85
Cell-specific processing of preprosomatostatin in cultured neuroendocrine cells.
Sevarino, K. A., Felix, R., Banks, C. M., Low, M. J., Montminy, M., Mandel, G., & Goodman, R. H. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61143-3 · Cited by 83
Janson, E., Stridsberg, M., Gobl, A., Westlin, J.-E., & Öberg, K. (1998) · PubMed · Cited by 81
Somatostatin receptor subtype gene expression in human endocrine gastroentero‐pancreatic tumours
Jais, P. H., Terris, B., Ruszniewski, P. B., Romancer, M. L., Reyl-Desmars, F., Vissuzaine, C., Cadiot, G., Mignon, M., & Lewin, M. J. M. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.1740719.x · Cited by 78
Ferone, D., van Hagen, M. P., Kwekkeboom, D. J., van Koetsveld, P. M., Mooy, D. M., Lichtenauer‐Kaligis, E., Schönbrunn, A., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6547 · Cited by 75
Self-citationRoth, A. J. K., Kreienkamp, H., Nehring, R. B., Roosterman, D., Meyerhof, W., & Richter, D. (1997) · DNA and Cell Biology · doi:10.1089/dna.1997.16.111 · Cited by 74
Xu, Y., Berelowitz, M., & Bruno, J. F. (1995) · Endocrinology · doi:10.1210/endo.136.11.7588243 · Cited by 73
Somatostatin Analogues for Somatostatin-Receptor-Mediated Radiotherapy of Cancer
Stolz, B., Smith-Jones, P. M., Albert, R., et al. (2009) · Digestion · doi:10.1159/000201387 · Cited by 72
Somatostatin receptors present knowledge and future directions
Schönbrunn, A. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s17 · Cited by 72
Kimura, N., Tomizawa, S., Arai, K. N., & Kimura, N. (1998) · Endocrinology · doi:10.1210/endo.139.4.5952 · Cited by 68
Kimura, N., Hayafuji, C., Konagaya, H., & Takahashi, K. (1986) · Endocrinology · doi:10.1210/endo-119-3-1028 · Cited by 64
Fates of endocytosed somatostatin sst2 receptors and associated agonists
Koenig, J., Kaur, R., DODGEON, I., Edwardson, J. M., & Humphrey, P. P. A. (1998) · Biochemical Journal · doi:10.1042/bj3360291 · Cited by 61
Visser-Wisselaar, H. A., van Uffelen, C. J. C., van Koetsveld, P. M., Lichtenauer-Kaligis, E. G. R., Waaijers, A. M., Uitterlinden, P., Mooy, D. M., Lamberts, S. W. J., & Hofland, L. J. (1997) · Endocrinology · doi:10.1210/endo.138.3.5016 · Cited by 54
Self-citationKimura, N., Hayafuji, C., & Kimura, N. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83536-0 · Cited by 53
Kiaris, H., Schally, A. V., Nagy, A., Szepesházi, K., Hébert, F., & Halmos, G. B. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00437-8 · Cited by 50
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.
Leimer, M., Kurtaran, A., Smith-Jones, P. M., Raderer, M., Havlik, E., Angelberger, P., Vorbeck, F., Niederle, B., Herold, C., & Virgolini, I. J. (1998) · PubMed · Cited by 50
Luthin, D. R., Eppler, C. M., & Linden, J. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53417-7 · Cited by 43
Szepesházi, K., Schally, A. V., Halmos, G., Sun, B., Hébert, F., Csernus, B., & Nagy, A. (2001) · PubMed · Cited by 41
Analysis of somatostatin receptor subtype mRNA expression in human breast cancer
Evans, A., Crook, T., Laws, S., Gough, A. C., Royle, G. T., & Primrose, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.143 · Cited by 39
Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae
Laws, S., Gough, A. C., Evans, A., Bains, M., & Primrose, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.59 · Cited by 37
Xu, Y. F., Berelowitz, M., & Bruno, J. F. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00072-0 · Cited by 36
Tamoxifen and somatostatin affect tumours by inducing apoptosis
Candi, E., Melino, G., Laurenzi, V. D., Piacentini, M., Guerrieri, P., Spinedi, A., & Knight, R. A. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)03924-l · Cited by 33
Cited by
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Metadata
- Authors
- Hofland, L. J., & Lamberts, S. W. J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2003-02-01
- Volume
- 24
- Issue
- 1
- Pages
- 28-47
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2140741951
- Cited by
- 474
- References
- 116
- FWCI
- 19.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.